Cadence Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Cadence Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-335,090	Closed	-$1.55M	–	313
2020 Q2	$1.55M	Buy	335,090 +13,962	+4%	+$62.7K	0.22%	131
2020 Q1	$1.24M	Sell	321,128 -16,593	-5%	-$68.1K	0.21%	147
2019 Q4	$1.27M	Sell	337,721 -33,354	-9%	-$156K	0.14%	217
2019 Q3	$1.97M	Buy	+371,075	New	+$1.98M	0.28%	144

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Cadence Capital Management's CPRX Position: Q3 2020 in Review

Cadence Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2020, closing a stake of 335,090 shares — an estimated $1.55M sold.

Cadence Capital Management first reported a position in CPRX in Q3 2019 and held it in 4 quarters. The position peaked at $1.97M in Q3 2019. 142 funds tracked by Wall St. Rank hold CPRX as of Q3 2020.

Cadence Capital Management reported no remaining Catalyst Pharmaceutical position as of Q3 2020 after selling out during the quarter.
Cadence Capital Management sold 335,090 Catalyst Pharmaceutical shares in Q3 2020, an estimated $1.55M.
Cadence Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2019 and held it in 4 quarters.
Cadence Capital Management's Catalyst Pharmaceutical position peaked at $1.97M in Q3 2019.
142 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.